(GLPG) Galapagos - Overview
Exchange: NASDAQ •
Country: Belgium •
Currency: USD •
Type: Common Stock •
ISIN: US36315X1019
Stock: Oncology Drugs, Immunology Drugs, Cell Therapy
Total Rating 51
Risk 72
Buy Signal 0.04
| Risk 5d forecast | |
|---|---|
| Volatility | 28.9% |
| Relative Tail Risk | -8.96% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.75 |
| Alpha | 14.50 |
| Character TTM | |
|---|---|
| Beta | 0.376 |
| Beta Downside | 0.595 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.03% |
| CAGR/Max DD | -0.11 |
EPS (Earnings per Share)
Revenue
Description: GLPG Galapagos March 10, 2026
Galapagos NV is a biotechnology company based in Belgium. It focuses on developing oncology and immunology medicines for the US and European markets.
The companys pipeline includes several drug candidates. GLPG3667 has completed Phase 1b trials. GLPG5101, GLPG5201, and GLPG5301 are all CAR-T cell therapy candidates in Phase 1/2 trials for various blood cancers. CAR-T cell therapies are a rapidly developing area within oncology, offering personalized treatment approaches.
Galapagos operates under a business model common in the biotechnology sector, involving extensive research and development, often leading to collaboration agreements for further development and commercialization. It currently has partnerships with Gilead Sciences and AbbVie.
Further research on ValueRay can provide detailed financials and competitive analysis.
Headlines to watch out for
- Pipeline drug trial results significantly impact stock valuation
- Regulatory approvals for new therapies drive revenue growth
- Collaboration milestones with Gilead and AbbVie boost income
- Research and development expenses affect profitability
- Competition in oncology and immunology markets impacts sales
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 320.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.08 > 0.02 and ΔFCF/TA 0.41 > 1.0 |
| NWC/Revenue: 263.0% < 20% (prev 1090 %; Δ -826.9% < -1%) |
| CFO/TA -0.07 > 3% & CFO -251.7m > Net Income 320.9m |
| Net Debt (-75.7m) to EBITDA (292.1m): -0.26 < 3 |
| Current Ratio: 20.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.9m) vs 12m ago -1.43% < -2% |
| Gross Margin: 56.02% > 18% (prev 0.52%; Δ 5550 % > 0.5%) |
| Asset Turnover: 29.50% > 50% (prev 6.67%; Δ 22.83% > 0%) |
| Interest Coverage Ratio: -7.88 > 6 (EBITDA TTM 292.1m / Interest Expense TTM 25.1m) |
Altman Z'' 8.61
| A: 0.86 (Total Current Assets 3.08b - Total Current Liabilities 152.8m) / Total Assets 3.41b |
| B: 0.06 (Retained Earnings 210.5m / Total Assets 3.41b) |
| C: -0.05 (EBIT TTM -198.0m / Avg Total Assets 3.77b) |
| D: 2.97 (Book Value of Equity 507.3m / Total Liabilities 170.6m) |
| Altman-Z'' Score: 8.61 = AAA |
Beneish M
| DSRI: 0.15 (Receivables 51.9m/88.1m, Revenue 1.11b/275.6m) |
| GMI: 0.93 (GM 56.02% / 52.09%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 4.03 (Revenue 1.11b / 275.6m) |
| TATA: 0.17 (NI 320.9m - CFO -251.7m) / TA 3.41b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of GLPG shares?
As of March 10, 2026, the stock is trading at USD 33.06 with a total of 83,895 shares traded.
Over the past week, the price has changed by -3.02%, over one month by -1.61%, over three months by +4.52% and over the past year by +27.99%.
Over the past week, the price has changed by -3.02%, over one month by -1.61%, over three months by +4.52% and over the past year by +27.99%.
Is GLPG a buy, sell or hold?
Galapagos has received a consensus analysts rating of 2.50.
Therefor, it is recommend to sell GLPG.
- StrongBuy: 0
- Buy: 0
- Hold: 4
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the GLPG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27.4 | -17.2% |
| Analysts Target Price | 27.4 | -17.2% |
GLPG Fundamental Data Overview March 10, 2026
P/E Forward = 303.0303
P/S = 1.9504
P/B = 0.7615
Revenue TTM = 1.11b USD
EBIT TTM = -198.0m USD
EBITDA TTM = 292.1m USD
Long Term Debt = 10.4m USD (estimated: total debt 12.1m - short term 1.73m)
Short Term Debt = 1.73m USD (from shortTermDebt, last quarter)
Debt = 12.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -75.7m USD (from netDebt column, last quarter)
Enterprise Value = -728.0m USD (2.26b + Debt 12.1m - CCE 3.00b)
Interest Coverage Ratio = -7.88 (Ebit TTM -198.0m / Interest Expense TTM 25.1m)
EV/FCF = 2.74x (Enterprise Value -728.0m / FCF TTM -265.5m)
FCF Yield = 36.47% (FCF TTM -265.5m / Enterprise Value -728.0m)
FCF Margin = -23.87% (FCF TTM -265.5m / Revenue TTM 1.11b)
Net Margin = 28.85% (Net Income TTM 320.9m / Revenue TTM 1.11b)
Gross Margin = 56.02% ((Revenue TTM 1.11b - Cost of Revenue TTM 489.1m) / Revenue TTM)
Gross Margin QoQ = 48.95% (prev 84.76%)
Tobins Q-Ratio = -0.21 (set to none) (Enterprise Value -728.0m / Total Assets 3.41b)
Interest Expense / Debt = 6.83% (Interest Expense 826.2k / Debt 12.1m)
Taxrate = 0.18% (1.40m / 771.3m)
NOPAT = -197.6m (EBIT -198.0m * (1 - 0.18%)) [loss with tax shield]
Current Ratio = 20.15 (Total Current Assets 3.08b / Total Current Liabilities 152.8m)
Debt / Equity = 0.00 (Debt 12.1m / totalStockholderEquity, last quarter 3.23b)
Debt / EBITDA = -0.26 (Net Debt -75.7m / EBITDA 292.1m)
Debt / FCF = 0.29 (negative FCF - burning cash) (Net Debt -75.7m / FCF TTM -265.5m)
Total Stockholder Equity = 2.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.51% (Net Income 320.9m / Total Assets 3.41b)
RoE = 11.16% (Net Income TTM 320.9m / Total Stockholder Equity 2.88b)
RoCE = -6.86% (EBIT -198.0m / Capital Employed (Equity 2.88b + L.T.Debt 10.4m))
RoIC = -7.56% (negative operating profit) (NOPAT -197.6m / Invested Capital 2.61b)
WACC = 7.30% (E(2.26b)/V(2.27b) * Re(7.30%) + D(12.1m)/V(2.27b) * Rd(6.83%) * (1-Tc(0.00)))
Discount Rate = 7.30% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.09%
[DCF] Fair Price = unknown (Cash Flow -265.5m)
EPS Correlation: -27.22 | EPS CAGR: 1.55% | SUE: 0.10 | # QB: 0
Revenue Correlation: 3.90 | Revenue CAGR: 65.45% | SUE: 4.0 | # QB: 1
EPS next Year (2026-12-31): EPS=-0.54 | Chg7d=-0.730 | Chg30d=-0.730 | Revisions Net=+1 | Growth EPS=+85.6% | Growth Revenue=-3.5%
P/S = 1.9504
P/B = 0.7615
Revenue TTM = 1.11b USD
EBIT TTM = -198.0m USD
EBITDA TTM = 292.1m USD
Long Term Debt = 10.4m USD (estimated: total debt 12.1m - short term 1.73m)
Short Term Debt = 1.73m USD (from shortTermDebt, last quarter)
Debt = 12.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -75.7m USD (from netDebt column, last quarter)
Enterprise Value = -728.0m USD (2.26b + Debt 12.1m - CCE 3.00b)
Interest Coverage Ratio = -7.88 (Ebit TTM -198.0m / Interest Expense TTM 25.1m)
EV/FCF = 2.74x (Enterprise Value -728.0m / FCF TTM -265.5m)
FCF Yield = 36.47% (FCF TTM -265.5m / Enterprise Value -728.0m)
FCF Margin = -23.87% (FCF TTM -265.5m / Revenue TTM 1.11b)
Net Margin = 28.85% (Net Income TTM 320.9m / Revenue TTM 1.11b)
Gross Margin = 56.02% ((Revenue TTM 1.11b - Cost of Revenue TTM 489.1m) / Revenue TTM)
Gross Margin QoQ = 48.95% (prev 84.76%)
Tobins Q-Ratio = -0.21 (set to none) (Enterprise Value -728.0m / Total Assets 3.41b)
Interest Expense / Debt = 6.83% (Interest Expense 826.2k / Debt 12.1m)
Taxrate = 0.18% (1.40m / 771.3m)
NOPAT = -197.6m (EBIT -198.0m * (1 - 0.18%)) [loss with tax shield]
Current Ratio = 20.15 (Total Current Assets 3.08b / Total Current Liabilities 152.8m)
Debt / Equity = 0.00 (Debt 12.1m / totalStockholderEquity, last quarter 3.23b)
Debt / EBITDA = -0.26 (Net Debt -75.7m / EBITDA 292.1m)
Debt / FCF = 0.29 (negative FCF - burning cash) (Net Debt -75.7m / FCF TTM -265.5m)
Total Stockholder Equity = 2.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.51% (Net Income 320.9m / Total Assets 3.41b)
RoE = 11.16% (Net Income TTM 320.9m / Total Stockholder Equity 2.88b)
RoCE = -6.86% (EBIT -198.0m / Capital Employed (Equity 2.88b + L.T.Debt 10.4m))
RoIC = -7.56% (negative operating profit) (NOPAT -197.6m / Invested Capital 2.61b)
WACC = 7.30% (E(2.26b)/V(2.27b) * Re(7.30%) + D(12.1m)/V(2.27b) * Rd(6.83%) * (1-Tc(0.00)))
Discount Rate = 7.30% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.09%
[DCF] Fair Price = unknown (Cash Flow -265.5m)
EPS Correlation: -27.22 | EPS CAGR: 1.55% | SUE: 0.10 | # QB: 0
Revenue Correlation: 3.90 | Revenue CAGR: 65.45% | SUE: 4.0 | # QB: 1
EPS next Year (2026-12-31): EPS=-0.54 | Chg7d=-0.730 | Chg30d=-0.730 | Revisions Net=+1 | Growth EPS=+85.6% | Growth Revenue=-3.5%